BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 9510461)

  • 1. Pharmacokinetics, dose adjustments, and 6-mercaptopurine/methotrexate drug interactions in two patients with thiopurine methyltransferase deficiency.
    Andersen JB; Szumlanski C; Weinshilboum RM; Schmiegelow K
    Acta Paediatr; 1998 Jan; 87(1):108-11. PubMed ID: 9510461
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Myelotoxicity after high-dose methotrexate in childhood acute leukemia is influenced by 6-mercaptopurine dosing but not by intermediate thiopurine methyltransferase activity.
    Levinsen M; Rosthøj S; Nygaard U; Heldrup J; Harila-Saari A; Jonsson OG; Bechensteen AG; Abrahamsson J; Lausen B; Frandsen TL; Weinshilboum RM; Schmiegelow K
    Cancer Chemother Pharmacol; 2015 Jan; 75(1):59-66. PubMed ID: 25347948
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Myelotoxicity, pharmacokinetics, and relapse rate with methotrexate/6-mercaptopurine maintenance therapy of childhood acute lymphoblastic leukemia.
    Schmiegelow K; Ifversen M
    Pediatr Hematol Oncol; 1996; 13(5):433-41. PubMed ID: 10897815
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 6-mercaptopurine dosage and pharmacokinetics influence the degree of bone marrow toxicity following high-dose methotrexate in children with acute lymphoblastic leukemia.
    Schmiegelow K; Bretton-Meyer U
    Leukemia; 2001 Jan; 15(1):74-9. PubMed ID: 11243403
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Methotrexate and 6-mercaptopurine maintenance therapy for childhood acute lymphoblastic leukemia: dose adjustments by white cell counts or by pharmacokinetic parameters?
    Schmiegelow K; Schrøder H; Schmiegelow M
    Cancer Chemother Pharmacol; 1994; 34(3):209-15. PubMed ID: 8004753
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mercaptopurine metabolite levels are predictors of bone marrow toxicity following high-dose methotrexate therapy of childhood acute lymphoblastic leukaemia.
    Vang SI; Schmiegelow K; Frandsen T; Rosthøj S; Nersting J
    Cancer Chemother Pharmacol; 2015 May; 75(5):1089-93. PubMed ID: 25788208
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DNA incorporation of 6-thioguanine nucleotides during maintenance therapy of childhood acute lymphoblastic leukaemia and non-Hodgkin lymphoma.
    Hedeland RL; Hvidt K; Nersting J; Rosthøj S; Dalhoff K; Lausen B; Schmiegelow K
    Cancer Chemother Pharmacol; 2010 Aug; 66(3):485-91. PubMed ID: 19956952
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic importance of 6-mercaptopurine dose intensity in acute lymphoblastic leukemia.
    Relling MV; Hancock ML; Boyett JM; Pui CH; Evans WE
    Blood; 1999 May; 93(9):2817-23. PubMed ID: 10216075
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of morning versus evening schedule for oral methotrexate and 6-mercaptopurine on relapse risk for children with acute lymphoblastic leukemia. Nordic Society for Pediatric Hematology and Oncology (NOPHO).
    Schmiegelow K; Glomstein A; Kristinsson J; Salmi T; Schrøder H; Björk O
    J Pediatr Hematol Oncol; 1997; 19(2):102-9. PubMed ID: 9149738
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Possible carcinogenic effect of 6-mercaptopurine on bone marrow stem cells: relation to thiopurine metabolism.
    Bo J; Schrøder H; Kristinsson J; Madsen B; Szumlanski C; Weinshilboum R; Andersen JB; Schmiegelow K
    Cancer; 1999 Sep; 86(6):1080-6. PubMed ID: 10491537
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk of relapse in childhood acute lymphoblastic leukemia is related to RBC methotrexate and mercaptopurine metabolites during maintenance chemotherapy. Nordic Society for Pediatric Hematology and Oncology.
    Schmiegelow K; Schrøder H; Gustafsson G; Kristinsson J; Glomstein A; Salmi T; Wranne L
    J Clin Oncol; 1995 Feb; 13(2):345-51. PubMed ID: 7531219
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 6-Thioguanine nucleotide accumulation in red blood cells during maintenance chemotherapy for childhood acute lymphoblastic leukemia, and its relation to leukopenia.
    Schmiegelow K; Bruunshuus I
    Cancer Chemother Pharmacol; 1990; 26(4):288-92. PubMed ID: 2369793
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of TPMT and ITPA variants in mercaptopurine disposition.
    Gerbek T; Ebbesen M; Nersting J; Frandsen TL; Appell ML; Schmiegelow K
    Cancer Chemother Pharmacol; 2018 Mar; 81(3):579-586. PubMed ID: 29387964
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Methotrexate/6-mercaptopurine maintenance therapy influences the risk of a second malignant neoplasm after childhood acute lymphoblastic leukemia: results from the NOPHO ALL-92 study.
    Schmiegelow K; Al-Modhwahi I; Andersen MK; Behrendtz M; Forestier E; Hasle H; Heyman M; Kristinsson J; Nersting J; Nygaard R; Svendsen AL; Vettenranta K; Weinshilboum R;
    Blood; 2009 Jun; 113(24):6077-84. PubMed ID: 19224761
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thiopurine methyltransferase deficiency in childhood lymphoblastic leukaemia: 6-mercaptopurine dosage strategies.
    Lennard L; Lewis IJ; Michelagnoli M; Lilleyman JS
    Med Pediatr Oncol; 1997 Oct; 29(4):252-5. PubMed ID: 9251729
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Methotrexate binds to recombinant thiopurine S-methyltransferase and inhibits enzyme activity after high-dose infusions in childhood leukaemia.
    Wennerstrand P; Mårtensson LG; Söderhäll S; Zimdahl A; Appell ML
    Eur J Clin Pharmacol; 2013 Sep; 69(9):1641-9. PubMed ID: 23660772
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thiopurine drugs in the treatment of childhood leukaemia: the influence of inherited thiopurine methyltransferase activity on drug metabolism and cytotoxicity.
    Lennard L; Welch JC; Lilleyman JS
    Br J Clin Pharmacol; 1997 Nov; 44(5):455-61. PubMed ID: 9384462
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus.
    Relling MV; Hancock ML; Rivera GK; Sandlund JT; Ribeiro RC; Krynetski EY; Pui CH; Evans WE
    J Natl Cancer Inst; 1999 Dec; 91(23):2001-8. PubMed ID: 10580024
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Maintenance therapy of childhood acute lymphoblastic leukemia revisited-Should drug doses be adjusted by white blood cell, neutrophil, or lymphocyte counts?
    Schmiegelow K; Nersting J; Nielsen SN; Heyman M; Wesenberg F; Kristinsson J; Vettenranta K; Schrøeder H; Weinshilboum R; Jensen KL; Grell K; Rosthoej S
    Pediatr Blood Cancer; 2016 Dec; 63(12):2104-2111. PubMed ID: 27447547
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects on transmethylation by high-dose 6-mercaptopurine and methotrexate infusions during consolidation treatment of acute lymphoblastic leukemia.
    Keuzenkamp-Jansen CW; De Abreu RA; Blom HJ; Bökkerink JP; Trijbels JM
    Biochem Pharmacol; 1996 May; 51(9):1165-71. PubMed ID: 8645339
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.